We are live on ! Find out more
NC

Nexthera Capital Portfolio holdings

AUM $120M
1-Year Est. Return 10.01%
This Fund
S&P 500
This Quarter Est. Return
+33.39%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$163M
AUM Growth
+$47.2M
Cap. Flow
+$28.1M
Cap. Flow %
17.24%
Top 10 Hldgs %
69.1%
Holding
47
New
12
Increased
10
Reduced
9
Closed
14

Top Buys

Rank Stock Value
1
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
+$4.25M
2
XLRN
Acceleron Pharma
XLRN
+$3.94M
3
IMMU
Immunomedics Inc
IMMU
+$3.53M
4
CLVS
Clovis Oncology, Inc.
CLVS
+$2.57M
5
ASND icon
Ascendis Pharma A/S
ASND
+$2.41M

Top Sells

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$6.05M
2
GSK icon
GSK
GSK
+$5.48M
3
AMGN icon
Amgen
AMGN
+$4.57M
4
CYNA
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
+$4.09M
5
LCI
Lannett Company, Inc.
LCI
+$1.92M

Sector Composition

Rank Sector Weight
1 Healthcare 69.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNTK icon
1
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2.16B
$26.5M 16.29%
+400,000
New +$23M
PFE icon
2
Pfizer
PFE
$142B
$22.2M 13.61%
689,370
+29,104
+4% +$973K
GSK icon
3
GSK
GSK
$102B
$14.9M 9.14%
276,000
-100,000
-27% -$5.48M
SHPG
4
DELISTED
Shire pic
SHPG
$13M 7.98%
67,000
-7,000
-9% -$1.37M
AZN icon
5
CALL
AstraZeneca
AZN
$263B
$8.21M 5.05%
+125,000
New +$8.17M
XLRN
6
DELISTED
Acceleron Pharma
XLRN
$7.88M 4.84%
217,817
+118,817
+120% +$3.94M
SGEN
7
DELISTED
Seagen Inc. Common Stock
SGEN
$6.02M 3.7%
111,500
-40,000
-26% -$1.9M
INSM icon
8
Insmed
INSM
$23.5B
$4.68M 2.87%
322,044
+153,344
+91% +$1.92M
ADMS
9
DELISTED
Adamas Pharmaceuticals
ADMS
$4.57M 2.81%
278,740
+100,500
+56% +$1.53M
NGNE icon
10
Neurogene
NGNE
$745M
$4.54M 2.79%
17,000
-7,915
-32% -$1.6M
LCI
11
DELISTED
Lannett Company, Inc.
LCI
$4.44M 2.73%
41,750
-15,750
-27% -$1.92M
CLVS
12
DELISTED
Clovis Oncology, Inc.
CLVS
$4.33M 2.66%
+120,000
New +$2.57M
IMMU
13
DELISTED
Immunomedics Inc
IMMU
$4.11M 2.52%
+1,263,276
New +$3.53M
CLCD
14
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$3.81M 2.34%
+100,000
New +$1.48M
EIGR
15
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$3.54M 2.17%
8,800
+8,333
+1,784% +$4.25M
ZGNX
16
DELISTED
Zogenix, Inc.
ZGNX
$2.97M 1.83%
+260,000
New +$2.4M
ASND icon
17
Ascendis Pharma A/S
ASND
$16.7B
$2.94M 1.81%
+146,200
New +$2.41M
KYNB
18
Kyntra Bio
KYNB
$28.5M
$2.64M 1.62%
5,107
-1,053
-17% -$496K
NDRM
19
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$2.42M 1.49%
+131,000
New +$2.27M
IMDZ
20
DELISTED
Immune Design Corp.
IMDZ
$2.31M 1.42%
305,000
+219,862
+258% +$1.61M
PGNX
21
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$2.22M 1.36%
350,000
+254,000
+265% +$1.54M
ADXS
22
DELISTED
Advaxis Inc
ADXS
$2.14M 1.31%
13,333
+5,000
+60% +$814K
TRVN
23
DELISTED
Trevena, Inc.
TRVN
$2.02M 1.24%
478
+238
+99% +$1.02M
ABEO icon
24
Abeona Therapeutics
ABEO
$372M
$1.93M 1.19%
12,864
+8,864
+222% +$867K
AERI
25
DELISTED
Aerie Pharmaceuticals
AERI
$1.89M 1.16%
50,000
-60,280
-55% -$1.33M
1
2

Similar funds

KAM
Kavi Asset Management New York $121M AUM 7.54% 1-Year Est. Return
VCP
Vernier Capital Partners New York $132M AUM 20.75% 1-Year Est. Return
PFC
Personal Financial Consultants Lafayette, California $133M AUM 5.06% 1-Year Est. Return
FCA
Florence Capital Advisors New York $105M AUM
TA
TMD & Associates Scottsdale, Arizona $146M AUM 1.29% 1-Year Est. Return
EBIM
Eagle Boston Investment Management Boston, Massachusetts $87.3M AUM 4.18% 1-Year Est. Return
BCM
BBT Capital Management Fort Worth, Texas $85.5M AUM 11.09% 1-Year Est. Return
ACP
ArcLight Capital Partners Boston, Massachusetts $83.2M AUM 32.11% 1-Year Est. Return

Nexthera Capital's Q3 2016 Portfolio in Review

As of Q3 2016, Nexthera Capital held 47 positions worth $163M, up 41% from $115M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Nexthera Capital deployed $28.1M of net new capital in Q3 2016, opening 12 new positions and adding to 10 existing holdings. Its largest new stake was Immunomedics Inc: 1,263,276 shares worth $4.11M.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, down from 90% a quarter earlier.

On the sell side, the largest reduction was GSK, an estimated $5.48M trimmed.

  • Nexthera Capital's largest Q3 2016 buy was Immunomedics Inc: 1,263,276 shares worth $4.11M.
  • Nexthera Capital added most to Eiger BioPharmaceuticals, Inc. in Q3 2016, an estimated $4.25M increase.
  • Nexthera Capital's biggest Q3 2016 reduction was GSK, cutting an estimated $5.48M.
  • Nexthera Capital fully exited Viatris in Q3 2016, selling an estimated $6.05M.
  • Nexthera Capital's ten largest holdings make up 69% of its $163M portfolio in Q3 2016.
  • Nexthera Capital opened 12 new positions and closed 14 in Q3 2016.
  • Nexthera Capital's portfolio value rose 41% quarter-over-quarter to $163M.

Based on Nexthera Capital's 13F filing for Q3 2016, filed 14 Nov 2016.